News

Vanda has entered into a License Agreement (the License Agreement) with Taro Pharmaceuticals U.S.A., Inc. and Taro Pharmaceutical Industries Ltd. (collectively, Taro) to resolve Vanda's patent litigation against

The company submitted a biologics licence application (BLA) to the US Food and Drug Administration (FDA) to market the vaccine for the prevention of herpes zoster (shingles) in

The phase 3 Keynote-045 trial demonstrated that Keytruda was superior compared to investigator choice chemotherapy. The drug’s safety profile was consistent with that observed in earlier reported trials

Faron has also recently received the second IDMC (Independent Data Monitoring Committee) recommendation to continue the INTEREST pan-European Phase III trial with Traumakine without any modifications. ARDS is

The first drug candidate within the expanded scope, (CAM2058), is an extended release injectable combination of buprenorphine and granisetron in the FluidCrystal® injection depot technology. CAM2058 has completed

One study showed that people with VTE taking XARELTO® for longer than three months had a lower risk of VTE recurrence, without an increase in major bleeding, compared

The company seeks to expand the use of Opdivo to patients with locally advanced unresectable or metastatic urothelial carcinoma (mUC) that has progressed on or after platinum-containing therapy. The

In the '482 study, a total of 1,718 patients were randomized to receive either subcutaneous XGEVA 120 mg and intravenous placebo every four weeks, or intravenous zoledronic acid

The recently initiated Phase II study is the first clinical investigation of SNF472 in patients with newly diagnosed calciphylaxis. Designed as an open-label investigation, eligible patients will be